Study #2024-0188
A phase IIIb, randomized, multicenter, open-label study to assess the efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in combination with platinum-based chemotherapy for first-line treatment in metastatic non-small cell lung cancer patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS (TRITON)
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
John Heymach
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-499-2252
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.